ConcertAI Launches New Generative and Agentic AI-Powered Precision Suite™ Accelerating Oncology Insights and Actions for Healthcare and Life Sciences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ConcertAI, a leader in oncology-focused generative and agentic AI solutions, today announced the launch of its new Precision Suite™. This groundbreaking family of AI-powered solutions redefines the way life sciences and healthcare organizations achieve actionable insights, optimize clinical trials, accelerate in-market execution, and drive improved patient outcomes while saving millions in cost. Powered by ConcertAI's proprietary CARAai™ platform and the unparalleled depth of its integrated Oncology Data, the Precision Suite delivers rapid, persona-tailored insights and enterprise-wide value.
The Precision Suite leverages CARAai's multi-modal, AI-curated data architecture to translate complex medical and genomic data into precise, real-world applications. These applications are built on a unique platform that is comprised of assistants, agents, LLMs and LRMs that are specifically designed and trained to support use cases in life sciences and healthcare. Its seamless integration of diverse data types enables life sciences teams to respond faster, make evidence-backed decisions, and maximize strategic impact. At launch, the suite includes three powerful applications tailored to distinct use cases across the healthcare ecosystem.
Precision Explorer™ empowers Health Economics and Outcomes Research (HEOR), epidemiology, and medical teams to uncover actionable insights within minutes. Generative AI and intuitive interfaces streamline cohort creation, outcomes analysis, and hypothesis testing, unlocking insights 2x faster than traditional methods, saving customers millions. With its ability to leverage curated oncology data and align with industry guidelines, such as ASCO® Standards, Precision Explorer ensures high-quality, citation-backed results.
Precision Trials™ transforms clinical trial operations by enabling smarter, faster decisions in study design, site selection, and patient recruitment. Powered by dynamic AI agents, this solution reduces costly trial amendments, improves site performance, and ensures diversity and enrollment goals are met. CARAai's advanced data-processing capabilities provide real-time assessments, shortening trial timelines with the potential to deliver $4M+ in cost savings for Phase II and III studies.
Precision GTM™ focuses on commercialization strategies for oncology therapies, unifying fragmented clinical, claims, and social determinants of health data. Harnessing CARAai's multi-modal insights, this platform enables brand teams to track the real-time standard of care, physician trends, and treatment pathways. By accelerating decision-making and enabling timely engagement, Precision GTM empowers teams to achieve faster, more impactful market execution while generating up to $7M in value for a typical oncology brand.
Precision360™, the backbone of ConcertAI's Precision Suite™, integrates EMR and genomic data alongside claims and social determinants of health information to create a revolutionary new RWD dataset. With AI-curation and a recency of less than a week, it provides real-time access to actionable insights, eliminating delays in oncology research and decisions. Designed for speed and efficiency, Precision360 provides accuracy and reliability, even in complex, unstructured datasets.
'Precision Suite is a testament to our commitment to innovation and patient-first outcomes,' said Eron Kelly, CEO of ConcertAI. 'Its ability to process complex, diverse datasets in near real-time has allowed us to deliver immediately actionable insights that will save customers millions in costs, while accelerating their time to market for life saving therapeutics. These new SaaS products are all built on our CARAai platform, the leading agentic AI platform built specifically for the needs of the life sciences enterprise.'
'ConcertAI serves 75% of the top life science companies and more than 50% of the largest global healthcare providers,' said Jeff Elton, Ph.D., Vice Chairman of ConcertAI. 'This launch signifies the evolution of ConcertAI from providing specialized solutions to delivering enterprise-class SaaS tools. Precision Suite aligns our expertise with our mission to deliver scalable, impactful solutions that redefine what's possible in life sciences and healthcare today.'
Precision Explorer™ and Precision Trials™ will be available beginning June 30, 2025. Precision GTM™ will follow with availability by July 31, 2025. With these solutions, ConcertAI solidifies its position as the leader in generative and agentic AI tailored for oncology and broader life sciences applications.
About ConcertAI:
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
2025 Zhejiang (Egypt) International Engineering Exhibition Successfully Held
RIYADH, Saudi Arabia & CAIRO--(BUSINESS WIRE)--From June 17th to 19th, 2025, the Zhejiang (Egypt) International Engineering Exhibition was successfully held in Hall 3 of the Cairo International Exhibition Center. Hosted by the Department of Commerce of Zhejiang Province and organized by the Zhejiang International Contractors Association and Hangzhou Boheng Business Exhibition Co., Ltd., the exhibition was held alongside the prominent 2025 Egypt Big 5 Construction Show. Zhejiang showcased its unified provincial image through a dedicated area featuring 10 enterprises, 15 representatives, and an exhibition space of 108 square meters. Participating companies included Yoking Pump Co., Ltd., Zhitao Electric Group Co., Ltd., Zhejiang Qiankai Electric Equipment Co., Ltd., and Hangzhou Fulltime Robotics Co., Ltd. Over three days, Zhejiang enterprises interacted with more than 920 professional merchants from 12 countries and regions, resulting in intended transaction amounts of $5.7 million. Strategically located at the crossroads of Asia, Africa, and Europe, Egypt plays a key role in the Belt and Road Initiative. In May 2024, China and Egypt signed the Cooperation Plan on Jointly Promoting the Construction of the Belt and Road Initiative, which defined key cooperation areas. This strengthened framework will deepen collaboration and fuel development. To diversify its economy, Egypt has initiated projects like 'Egypt Vision 2030,' the New Administrative Capital, and the Suez Canal Corridor—sectors with strong demand for construction and renewable energy. These developments open new avenues for Zhejiang enterprises to participate in Egypt's infrastructure upgrades. Zhejiang Province has been advancing its 'Sweet Potato Economy' strategy to upgrade the 'No. 1 Opening-Up Project.' In 2024, newly signed foreign contracting projects totaled $5.486 billion (up 11.57%), with a completed turnover of $7.995 billion (up 15.27%), ranking fourth nationwide in business scale. This Egyptian exhibition marked Zhejiang's first self-organized overseas event in 2025. Themed 'Shaping a Smart, Green Future with Zhejiang,' it underscored the province's capabilities in green technology and smart construction. Zhejiang will continue to leverage overseas exhibitions to help more enterprises expand globally, foster cooperation and technology exchange, and offer sustainable solutions to global engineering challenges.
Business Wire
12 hours ago
- Business Wire
U-Haul Offers Disaster Relief After Derecho Hits North Dakota, Minnesota
FARGO, N.D.--(BUSINESS WIRE)--U-Haul ® is extending 30 days of free self-storage and U-Box ® container usage at seven centers across eastern North Dakota and northern Minnesota to residents affected by tornadoes that left a wide path of destruction Friday night and into the early hours of Saturday. U-Haul is extending 30 days of free self-storage and U-Box container usage at seven centers in North Dakota and Minnesota to residents impacted by the derecho. Share A derecho with winds exceeding 100 mph moved across numerous counties in both states, damaging properties and leaving thousands without power. There were multiple tornado sightings throughout the fast-moving storm system. Enderlin, N.D., located southwest of Fargo, and Bemidji, Minn., were among the communities hardest hit. Access to dry and secure self-storage and portable storage containers can be vital to communities during the clean-up and recovery process after natural disasters. The 30 days free offer applies to new self-storage and U-Box rentals and is based on availability. The U-Box offer is for on-site storage at Company centers, and for customers who tow their portable storage container. U-Box delivery and pick-up is also available for a modest cost. People seeking more information on the disaster relief program or needing to arrange storage services can contact the nearest participating U-Haul facility: NORTH DAKOTA U-Haul Moving & Storage of 13th Ave. 4901 13th Ave S. Fargo, ND 58103 (701) 205-3260 U-Haul Moving & Storage of Fargo 1436 Main Ave. Fargo, ND 58103 (701) 293-5256 U-Haul Moving & Storage of Osgood 5200 Veterans Blvd. Fargo, ND 58104 (701) 492-8900 U-Haul Storage of Fargo 610 42nd St. N. Fargo, ND 58102 (701) 639-7714 MINNESOTA U-Haul Moving & Storage of Moorhead 50 County Road 9 Dilworth, MN 56529 (218) 303-1480 U-Haul Storage of Nisswa 4745 County Road 77 Nisswa, MN 56468 (218) 963-5106 U-Haul Storage North Baxter 15237 Edgewood Dr. Brainerd, MN 56401 (218) 297-3018 In addition to its 30 days free self-storage disaster relief program, U-Haul is proud to be at the forefront of aiding communities in times of need as an official American Red Cross Disaster Responder. About U-HAUL Celebrating our 80th anniversary in 2025, U-Haul is the No. 1 choice of do-it-yourself movers with more than 24,000 rental locations across all 50 states and 10 Canadian provinces. The U-Haul app makes it easy for customers to use U-Haul Truck Share 24/7 to access trucks anytime through the self-dispatch and -return options on their smartphones with our patented Live Verify technology. Our customers' patronage has enabled the U-Haul fleet to grow to 193,900 trucks, 138,200 trailers and 40,300 towing devices. U-Haul is the third largest self-storage operator in North America and offers 1,060,000 rentable storage units and 92.0 million square feet of self-storage space at owned and managed facilities. U-Haul is the top retailer of propane in the U.S. and the largest installer of permanent trailer hitches in the automotive aftermarket industry. Get the U-Haul app from the App Store or Google Play.
Business Wire
a day ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
